Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.

Dr Jallouk on Preventing Post-Transplant Relapse in R/R Hematologic Malignancies

May 2nd 2024

Andrew P. Jallouk, BS, MD, PhD, discusses research assessing post-transplant relapse prevention strategies in patients with hematologic malignancies.

Dr Jabbour on the Results of the PhALLCON Trial in Newly Diagnosed Ph+ ALL

May 1st 2024

Elias Jabbour, MD, discusses outcomes from the phase 3 PhALLCON trial in patients with Ph-positive acute lymphoblastic leukemia.

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

May 1st 2024

SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.

NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML

April 30th 2024

The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.

Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL

April 30th 2024

Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.

Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

April 29th 2024

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Dr Fedorov on the Use of Quizartinib vs Midostaurin in FLT3+ AML

April 26th 2024

Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.

Dr Pantin on the Evolving Treatment Paradigm in PNH

April 25th 2024

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.

Dr Annie Im: How to Treat Acute Myeloid Leukemia in 2024

April 25th 2024

Annie Im, MD, FASCO, University of Pittsburgh/UPMC Hillman Cancer Center, discusses the various modern approaches for the treatment of patients with acute myeloid leukemia.

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

April 25th 2024

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024

Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.

Dr Ignatz-Hoover on the Evolving Use of Blinatumomab in ALL

April 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the implications of utilizing blinatumomab to treat acute lymphoblastic leukemia.

Dr Marc Braunstein: Program Building, Education in Hematologic Cancers

April 23rd 2024

Marc J. Braunstein, MD, PhD, FACP, of NYU Grossman Long Island School of Medicine, discusses lessons learned with program building and medical education with hematologic cancers.

Dr Coombs on the Ongoing Investigation of Quizartinib in AML

April 22nd 2024

Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

April 22nd 2024

The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

April 19th 2024

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.